Vancomycin Therapeutic Drug Monitoring (TDM) and Its Association with Clinical Outcomes: A Retrospective Cohort

被引:24
作者
Al-Maqbali, Juhaina Salim [1 ]
Al Shukri, Zahra [2 ]
Al Sabahi, Nawf [2 ]
AL-Riyami, Intisar [1 ]
Al Alawi, Abdullah M. [2 ,3 ]
机构
[1] Sultan Qaboos Univ Hosp, Dept Pharm, Muscat, Oman
[2] Oman Med Specialty Board, Muscat, Oman
[3] Sultan Qaboos Univ Hosp, Dept Med, Muscat, Oman
关键词
Therapeutic drug monitoring; Vancomycin-induced nephrotoxicity; Therapeutic failure; All-cause mortality; TROUGH CONCENTRATIONS; SERUM CONCENTRATIONS; NEPHROTOXICITY; INFECTIONS;
D O I
10.1016/j.jiph.2022.04.007
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Therapeutic drug monitoring (TDM) has proven effectiveness in maintaining efficacy and re-ducing toxicities associated with vancomycin. A trough level of (15-20 mg/L) for MRSA serious infections is recommended. Therapeutic failure is of concern due to suboptimal routine vancomycin utilization in clinical practice. This study aims to identify factors of vancomycin TDM practice potentially associated with van-comycin-induced nephrotoxicity and therapeutic failure measured by the need to restart vancomycin therapy within 28-days and all-cause mortality in a tertiary hospital in Oman.Methods: A single-center retrospective cohort was conducted in a tertiary care hospital that included all adult patients aged >= 18 years treated with IV vancomycin for > 72 h.Results: Vancomycin therapeutic level was not achieved in 16.8% of the patients, and 47.5% had high levels (> 20 mg/L). Vancomycin-induced nephrotoxicity occurred in 31.7% of the patients, it was restarted within 28-days in 18.8% of the patient, and 25.2% of the patients died during the same hospitalization. Univariate analysis showed old age (p < 0.01), higher baseline creatinine reading (p = 0.03), high vancomycin level (p = 0.03), and vancomycin-induced nephrotoxicity (p < 0.01) were associated with increased all-cause mortality. Multivariate analysis identified overweight and vancomycin-induced nephrotoxicity were in-dependent factors associated with increased all-cause mortality (OR:1.04; p = 0.043; 95% CI 1.00-1.08) and (OR:1.96; p = 0.049; 95% CI 1.00-21.61) respectively.Conclusion: Failure to achieve the recommended therapeutic vancomycin level (15-20 mg/L) is common in clinical practice and associated with poor health outcomes; hence, appropriate TDM practice is an essential exercise to improve efficacy, prevent failure and reduce serious toxicities associated with vancomycin therapy. (c) 2022 The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. CC_BY_NC_ND_4.0
引用
收藏
页码:589 / 593
页数:5
相关论文
共 27 条
[1]   Clinical and Pharmacokinetic Outcomes of Peak-Trough-Based Versus Trough-Based Vancomycin Therapeutic Drug Monitoring Approaches: A Pragmatic Randomized Controlled Trial [J].
Al-Sulaiti, Fatima Khalifa ;
Nader, Ahmed Mohamed ;
Saad, Mohamed Omar ;
Shaukat, Adila ;
Parakadavathu, Rakesh ;
Elzubair, Ahmed ;
Al-Badriyeh, Daoud ;
Elewa, Hazem ;
Awaisu, Ahmed .
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2019, 44 (05) :639-652
[2]   Optimizing the Clinical Use of Vancomycin [J].
Alvarez, Rocio ;
Lopez Cortes, Luis E. ;
Molina, Jose ;
Cisneros, Jose M. ;
Pachon, Jeronimo .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (05) :2601-2609
[3]   Relationship between Vancomycin Trough Concentrations and Nephrotoxicity: a Prospective Multicenter Trial [J].
Bosso, John A. ;
Nappi, Jean ;
Rudisill, Celeste ;
Wellein, Marlea ;
Bookstaver, P. Brandon ;
Swindler, Jenna ;
Mauldin, Patrick D. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (12) :5475-5479
[4]   Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review [J].
Elyasi, Sepideh ;
Khalili, Hossein ;
Dashti-Khavidaki, Simin ;
Mohammadpour, Amirhooshang .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 68 (09) :1243-1255
[5]   Uncomplicated acute renal failure and hospital resource utilization: A retrospective multicenter analysis [J].
Fischer, MJ ;
Brimhall, BB ;
Lezotte, DC ;
Glazner, JE ;
Parikh, CR .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2005, 46 (06) :1049-1057
[6]   The Whole Price of Vancomycin: Toxicities, Troughs, and Time [J].
Jeffres, Meghan N. .
DRUGS, 2017, 77 (11) :1143-1154
[7]   A Multicenter Evaluation of Vancomycin-Associated Acute Kidney Injury in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections [J].
Jorgensen, Sarah C. J. ;
Murray, Kyle P. ;
Lagnf, Abdalhamid M. ;
Melvin, Sarah ;
Bhatia, Sahil ;
Shamim, Muhammad-Daniayl ;
Smith, Jordan R. ;
Brade, Karrine D. ;
Simon, Samuel P. ;
Nagel, Jerod ;
Williams, Karen S. ;
Ortwine, Jessica K. ;
Veve, Michael P. ;
Truong, James ;
Huang, David B. ;
Davis, Susan L. ;
Rybak, Michael J. .
INFECTIOUS DISEASES AND THERAPY, 2020, 9 (01) :89-106
[8]   Prospective evaluation of vancomycin therapeutic usage and trough levels monitoring [J].
Kabbara, Wissam K. ;
El-Khoury, Ghada ;
Chamas, Nour R. .
JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, 2018, 12 (11) :978-984
[9]   KDIGO Clinical Practice Guidelines for Acute Kidney Injury [J].
Khwaja, Arif .
NEPHRON CLINICAL PRACTICE, 2012, 120 (04) :C179-C184
[10]   Effects of Targeting Higher Vancomycin Trough Levels on Clinical Outcomes and Costs in a Matched Patient Cohort [J].
Kullar, Ravina ;
Davis, Susan L. ;
Taylor, Thomas N. ;
Kaye, Keith S. ;
Rybak, Michael J. .
PHARMACOTHERAPY, 2012, 32 (03) :195-201